Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 4/20 | 0.46 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.46 |
| ▸ | TUBB | P07437 | 2/20 | 0.46 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.46 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.46 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.46 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.46 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.46 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.46 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.46 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.46 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.46 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.46 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.46 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.46 |
| ▸ | NQO1 | P15559 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950363 | 1.00 | EGFR (0.51) | EGFRKDM4EPKMTNFRSF1ATUBB1 | |
| SCHEMBL4325325 | 1.00 | EGFR (0.51) | EGFRKDM4EPKMTNFRSF1ATUBB1 | |
| SCHEMBL11549417 | 0.90 | NQO1 (0.54) | EGFRKDM4ETUBB1TUBB4ATUBB | |
| SCHEMBL11549421 | 0.90 | NQO1 (0.54) | EGFRKDM4ETUBB1TUBB4ATUBB | |
| SCHEMBL4330242 | 0.82 | EGFR (0.73) | EGFRKDM4EPKMTNFRSF1ATUBB1 | |
| SCHEMBL9124372 | 0.81 | EGFR (0.58) | EGFRKDM4EMAPTHPGDPTP4A3 | |
| SCHEMBL9124369 | 0.81 | EGFR (0.58) | EGFRKDM4EMAPTHPGDPTP4A3 | |
| SCHEMBL28071871 | 0.80 | EGFR (0.54) | EGFRKDM4EPKMTNFRSF1ATUBB1 | |
| SCHEMBL28071873 | 0.80 | EGFR (0.54) | EGFRKDM4EPKMTNFRSF1ATUBB1 | |
| SCHEMBL22259980 | 0.78 | KDM4E (0.75) | EGFRKDM4EPKMMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7476741-B2 | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. | 2005-08-11 | — | — | US | disclosed |
| EP-1513515-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003096982-A2 | SUBSTITUTED 4H-CHROMENES, 2H-CHROMENES, CHROMANS AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2003-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176750-A1 | Substituted 4h-chromens, 2h-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP4, CASP10 | EGFR 2560/4885KDM4E 607/4885PKM 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.